INJE PharmacoGenomics Research Center

· Tien NTN, Binh VN, Ha PTT, Lan DTN, Cho YS, Long NP, Shin JG, Anh NH(Jr), Quan TA, Tuan DN, Tiep NK, Thach PT, Anh NH, Hoa VD

Optimization of meropenem continuous infusion based on Monte Carlo simulation integrating with degradation study (cPMTb)

PLoS One. 23;19(12):e0313764 / 2024.12 [LINK]

· Bu F, Cho YS, He Q, Wang X, Howlader S, Kim DH, Zhu M, Shin JG, Xiang X

Prediction of Pharmacokinetic Drug-Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling (cPMTb)

Drug Des Devel Ther. 15:18:4585-4600 / 2024.10 [LINK]

· Park YM, Tung PM, Anh NK, Cho YS, Shin JG

Application of the Hollow-Fiber Infection Model to Personalized Precision Dosing of Isoniazid in a Clinical Setting (cPMTb)

J Korean Med Sci. 8;39(13):e104 / 2024.04 [LINK]

· Hoa PQ, Kim HK, Jang TW, Seo HW, Oh JY, Kim HC, Shin AY, Min JS, Jayanti RP, Hung TM, Anh NK, Ahn SZ, Long NP, Cho YS, Shin JG, cPMTb

Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: Effects of SLCO1B1 polymorphisms on drug exposure (cPMTb)

Int J Antimicrob Agents. 63(2):107034 / 2024.02 [LINK]

· Moon JJ, Kim HS, Shim JC, Ahn JM, Jung DU, Kim DJ, Jeong HE, Kim EY, Jeon DW, Kim SJ, Shin JG

Possible genetic biomarker associated with antipsychotic-induced amenorrhea in female patients with schizophrenia (cPMTb)

Int Clin Psychopharmacol. 1;39(1):29-35 / 2024.01 [LINK]

· Seo WJ, Koo HK, Kang JY, Kang JE, Park SH, Kang HK, Park HK, Lee SS, Choi SB, Jang TW, Shin KC, Oh JY, Choi JY, Min JS, Choi YK, Shin JG, Cho YS

Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort database (cPMTb)

BMC Pulm Med. 24;23(1):471 / 2023.11 [LINK]

· Phat NK, Tien NTM, Anh NK, Yen NTH, Lee YA, Trinh HKT, Le KM, Ahn SZ, Cho YS, Park SO, Kim DH, Long NP, Shin JG

Alterations of lipid-related genes during anti-tuberculosis treatment: insights into host immune responses and potential transcriptional biomarkers (cPMTb)

Front Immunol. 31:14:1210372 / 2023.10 [LINK]

· Yen NTH, Phat NK, Oh JH, Park SM, Moon KS, Thu VTA, Cho YS, Shin JG, Long NP, Kim DH

Pathway-level multi-omics analysis of the molecular mechanisms underlying the toxicity of long-term tacrolimus exposure (cPMTb)

Toxicol Appl Pharmacol. 15:473:116597 / 2023.08 [LINK]

· Hung TM, Jayanti RP, Lee HY, Kim HJ, Mok JH, Jang TW, Oh JY, Kim JS, Ko YS, Min JS, Hoa PQ, Ahn SZ, Long NP, Cho YS, Shin JG, cPMTb

Recommendation of pharmacokinetics/pharmacodynamics target of ethambutol to suppress tuberculosis resistance: A population pharmacokinetics study on a large prospective cohort (cPMTb)

Int J Antimicrob Agents. 62(2):106840 / 2023.08 [LINK]

· Yen NTH, Anh NK, Jayanti RP, Phat NK, Vu DH, Ghim JL, Ahn SZ, Shin JG, Oh JY, Long NP, Kim DH

Multimodal plasma metabolomics and lipidomics in elucidating metabolic perturbations in tuberculosis patients with concurrent type 2 diabetes (cPMTb)

Biochimie. 211:153-163 / 2023.08 [LINK]

Publications

Product